<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39468971</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Alimentary pharmacology &amp; therapeutics</Title><ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.18349</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Variant-adapted COVID-19 vaccines are recommended for patients with inflammatory bowel disease (IBD). However, many patients rely on pre-existing immunity by original vaccines or prior infections.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess whether such immunity sufficiently combats the highly immune-evasive SARS-CoV-2 JN.1 variant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Utilising two longitudinal cohorts, we evaluated immunity against JN.1 induced by original vaccines (IBD: n = 98; healthy: n = 48), omicron breakthrough infection (IBD: n = 55; healthy: n = 57) or XBB.1.5-adapted vaccines (IBD: n = 18). Neutralisation and anti-receptor-binding domain (RBD) IgG levels against wild-type SARS-CoV-2 and JN.1 were assessed using multiplex immunoassays. Study outcomes were wild-type and JN.1 neutralisation following three doses of original mRNA vaccines, stratified by immunosuppressive therapy (primary outcome), and JN.1 neutralisation following third-dose breakthrough infection or a fourth dose of XBB.1.5-adapted mRNA vaccines (secondary outcomes).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Following original vaccines, JN.1 neutralisation was lower than wild-type neutralisation in all study groups (healthy, anti-TNF and non-anti-TNF; each p &lt; 0.001); most individuals lacked JN.1 neutralisation (healthy: 97.9%; anti-TNF: 98.3% and non-anti-TNF: 92.3%). Confounder-adjusted multivariable modelling strongly associated anti-TNF therapy with low levels of anti-JN.1-RBD IgG (fold-change 0.48 [95% CI 0.39-0.59]). JN.1 neutralisation was similar in patients with or without breakthrough infection (anti-TNF, non-anti-TNF; each p &gt; 0.05); neutralisation failure was 100% despite breakthrough infection. XBB.1.5-adapted vaccines enhanced JN.1 neutralisation (p &lt; 0.001) and reduced neutralisation failure rates in patients with IBD (94.4% pre-vaccination vs. 44.4% post-vaccination; p = 0.003).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Only variant-adapted vaccines protect against emerging SARS-CoV-2 variants. Patients with IBD and healthy individuals without recent vaccination may lack protection against the JN.1 subvariant KP.3 which causes current COVID-19 surges.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woelfel</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2528-0582</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dütschler</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Outpatient Clinic, Ambulatory Services Rorschach, Rorschach, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junker</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>König</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Trials Unit, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truniger</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Outpatient Clinic, Ambulatory Services Rorschach, Rorschach, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikonomou</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leinenkugel</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>Seraina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger-Peter</LastName><ForeName>Katline</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krupka</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>STAR SIGN Study Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Albrich</LastName><ForeName>Werner C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niess</LastName><ForeName>Jan Hendrik</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology Group, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneiderhan-Marra</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dulovic</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misselwitz</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Clinic II, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Laboratory Medicine, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bürgi</LastName><ForeName>Justus J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Center for Laboratory Medicine, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7011-0430</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>University of Oxford</Agency><Country /></Grant><Grant><GrantID>101003480-CORESMA</GrantID><Agency>HORIZON Europe European Research Council</Agency><Country /></Grant><Grant><GrantID>FKZ 3-4332.62-NMI-68</GrantID><Agency>State Ministry of Baden-Württemberg for Economic Affairs, Labor, and Tourism</Agency><Country /></Grant><Grant><GrantID>FKZ-3-4332.62-NMI-67</GrantID><Agency>State Ministry of Baden-Württemberg for Economic Affairs, Labor, and Tourism</Agency><Country /></Grant><Grant><GrantID>23/26</GrantID><Agency>Cantonal Hospital St. Gallen</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">Crohn's disease</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">adapted COVID‐19 vaccines</Keyword><Keyword MajorTopicYN="N">anti‐TNF therapy</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">infliximab</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468971</ArticleId><ArticleId IdType="doi">10.1111/apt.18349</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>D. Y. Lin, Y. Du, Y. Xu, et al., “Durability of XBB.1.5 Vaccines Against Omicron Subvariants,” New England Journal of Medicine 390, no. 22 (2024): 2124–2127.</Citation></Reference><Reference><Citation>Y. Xie, T. Choi, and A.‐A. Ziyad, “Postacute Sequelae of SARS‐CoV‐2 Infection in the Pre‐Delta, Delta, and Omicron Eras,” New England Journal of Medicine 391, no. 6 (2024): 515–525.</Citation></Reference><Reference><Citation>A. M. Carabelli, T. P. Peacock, L. G. Thorne, W. T. Harvey, and J. Hughes, “COVID‐19 Genomics UK Consortium, Et al. SARS‐CoV‐2 Variant Biology: Immune Escape, Transmission and Fitness,” Nature Reviews. Microbiology 21, no. 3 (2023): 162–177.</Citation></Reference><Reference><Citation>L. Premkumar, B. Segovia‐Chumbez, R. Jadi, et al., “The Receptor‐Binding Domain of the Viral Spike Protein Is an Immunodominant and Highly Specific Target of Antibodies in SARS‐CoV‐2 Patients,” Science Immunology 5, no. 48 (2020): eabc8413.</Citation></Reference><Reference><Citation>S. Yang, Y. Yu, Y. Xu, et al., “Fast Evolution of SARS‐CoV‐2 BA.2.86 to JN.1 Under Heavy Immune Pressure,” Lancet Infectious Diseases 24, no. 2 (2024): e70–e72.</Citation></Reference><Reference><Citation>T. Nyberg, N. M. Ferguson, S. G. Nash, et al., “Comparative Analysis of the Risks of Hospitalisation and Death Associated With SARS‐CoV‐2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England: A Cohort Study,” Lancet 399, no. 10332 (2022): 1303–1312.</Citation></Reference><Reference><Citation>S. C. Ng, H. Y. Shi, N. Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population‐Based Studies,” Lancet 390, no. 10114 (2017): 2769–2778.</Citation></Reference><Reference><Citation>J. L. Alexander, Z. Liu, D. Muñoz Sandoval, et al., “COVID‐19 Vaccine‐Induced Antibody and T‐Cell Responses in Immunosuppressed Patients With Inflammatory Bowel Disease After the Third Vaccine Dose (VIP): A Multicentre, Prospective, Case‐Control Study,” Lancet Gastroenterology &amp; Hepatology 7, no. 11 (2022): 1005–1015.</Citation></Reference><Reference><Citation>H. Edelman‐Klapper, E. Zittan, A. Bar‐Gil Shitrit, et al., “Lower Serologic Response to COVID‐19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti‐TNFα,” Gastroenterology 162, no. 2 (2022): 454–467.</Citation></Reference><Reference><Citation>S. Woelfel, J. Dütschler, M. König, et al., “Systemic and T Cell‐Associated Responses to SARS‐CoV‐2 Immunisation in Gut Inflammation (STAR SIGN Study): Effects of Biologics on Vaccination Efficacy of the Third Dose of mRNA Vaccines Against SARS‐CoV‐2,” Alimentary Pharmacology &amp; Therapeutics 57, no. 1 (2023): 103–116.</Citation></Reference><Reference><Citation>N. A. Kennedy, M. Janjua, N. Chanchlani, et al., “Vaccine Escape, Increased Breakthrough and Reinfection in Infliximab‐Treated Patients With IBD During the Omicron Wave of the SARS‐CoV‐2 Pandemic,” Gut 72, no. 2 (2023): 295–305.</Citation></Reference><Reference><Citation>Z. Liu, K. Le, X. Zhou, et al., “Neutralising Antibody Potency Against SARS‐CoV‐2 Wild‐Type and Omicron BA.1 and BA.4/5 Variants in Patients With Inflammatory Bowel Disease Treated With Infliximab and Vedolizumab After Three Doses of COVID‐19 Vaccine (CLARITY IBD): An Analysis of a Prospective Multicentre Cohort Study,” Lancet Gastroenterología y Hepatología 8, no. 2 (2023): 145–156.</Citation></Reference><Reference><Citation>HDR UK COALESCE Consortium, “Undervaccination and Severe COVID‐19 Outcomes: Meta‐Analysis of National Cohort Studies in England, Northern Ireland, Scotland, and Wales,” Lancet 403, no. 10426 (2024): 554–566.</Citation></Reference><Reference><Citation>E. Tessier, Y. Rai, E. Clarke, et al., “Characteristics Associated With COVID‐19 Vaccine Uptake Among Adults Aged 50 Years and Above in England (8 December 2020–17 May 2021): A Population‐Level Observational Study,” British Medical Journal Open 12, no. 3 (2022): e055278.</Citation></Reference><Reference><Citation>Health Alert Network (HAN) ‐ 00503 | “Urgent Need to Increase Immunization Coverage for Influenza, COVID‐19, and RSV and Use of Authorized/Approved Therapeutics in the Setting of Increased Respiratory Disease Activity DURING the 2023–2024 Winter Season,” 2023, https://emergency.cdc.gov/han/2023/han00503.asp.</Citation></Reference><Reference><Citation>Y. Kaku, M. S. Yo, J. E. Tolentino, K. Uriu, and K. Okumura, “Genotype to Phenotype Japan (G2P‐Japan) Consortium, Et al. Virological Characteristics of the SARS‐CoV‐2 KP.3, LB.1, and KP.2.3 Variants,” Lancet Infectious Diseases 24, no. 8 (2024): e482–e483.</Citation></Reference><Reference><Citation>S. Woelfel, J. Dütschler, M. König, et al., “STAR SIGN Study: Evaluation of COVID‐19 Vaccine Efficacy Against the SARS‐CoV‐2 Variants BQ.1.1 and XBB.1.5 in Patients With Inflammatory Bowel Disease,” Alimentary Pharmacology &amp; Therapeutics 58, no. 7 (2023): 678–691.</Citation></Reference><Reference><Citation>S. Woelfel, J. Dütschler, D. Junker, et al., “Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5‐Adapted COVID‐19 mRNA Vaccines in Patients With Inflammatory Bowel Disease,” Vaccine 12, no. 7 (2024): 774.</Citation></Reference><Reference><Citation>P. B. Gilbert, D. C. Montefiori, A. B. McDermott, et al., “Immune Correlates Analysis of the mRNA‐1273 COVID‐19 Vaccine Efficacy Clinical Trial,” Science 375, no. 6576 (2022): 43–50.</Citation></Reference><Reference><Citation>S. Y. Tartof, J. M. Slezak, T. B. Frankland, et al., “Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID‐19,” Journal of the American Medical Association Internal Medicine 184, no. 8 (2024): 932–940.</Citation></Reference><Reference><Citation>J. Quan, A. Markovinović, L. Hracs, et al., “Bivalent mRNA SARS‐CoV‐2 Vaccination in Patients With Inflammatory Bowel Disease,” Lancet Gastroenterology &amp; Hepatology 8, no. 12 (2023): 1074–1075.</Citation></Reference><Reference><Citation>Y. Lustig, N. Barda, Y. Weiss‐Ottolenghi, et al., “Humoral Response Superiority of the Monovalent XBB.1.5 Over the Bivalent BA.1 and BA.5 mRNA COVID‐19 Vaccines,” Vaccine 42, no. 22 (2024): 126010.</Citation></Reference><Reference><Citation>C. M. Trombetta, O. Kistner, E. Montomoli, S. Viviani, and S. Marchi, “Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines,” Vaccine 10, no. 5 (2022): 714.</Citation></Reference><Reference><Citation>Q. Wang, Y. Guo, A. Bowen, et al., “XBB.1.5 Monovalent mRNA Vaccine Booster Elicits Robust Neutralizing Antibodies Against XBB Subvariants and JN.1,” Cell Host &amp; Microbe 32, no. 3 (2024): 315–321. e3.</Citation></Reference><Reference><Citation>D. Tassone, A. Thompson, W. Connell, et al., “Immunosuppression as a Risk Factor for COVID‐19: A Meta‐Analysis,” Internal Medicine Journal 51, no. 2 (2021): 199–205.</Citation></Reference><Reference><Citation>M. Agrawal, X. Zhang, E. J. Brenner, R. C. Ungaro, M. D. Kappelman, and J. F. Colombel, “The Impact of Vedolizumab on COVID‐19 Outcomes Among Adult IBD Patients in the SECURE‐IBD Registry,” Journal of Crohn's &amp; Colitis 15, no. 11 (2021): 1877–1884.</Citation></Reference><Reference><Citation>R. Parekh, X. Zhang, R. C. Ungaro, et al., “Presence of Comorbidities Associated With Severe Coronavirus Infection in Patients With Inflammatory Bowel Disease,” Digestive Diseases and Sciences 67, no. 4 (2022): 1271–1277.</Citation></Reference><Reference><Citation>R. C. Ungaro, E. J. Brenner, M. Agrawal, X. Zhang, M. D. Kappelman, and J. F. Colombel, “Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE‐IBD) Research Group. Impact of Medications on COVID‐19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry,” Gastroenterology 162, no. 1 (2022): 316–319.e5.</Citation></Reference><Reference><Citation>Z. Izadi, E. J. Brenner, S. K. Mahil, et al., “Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune‐Mediated Inflammatory Disease and COVID‐19,” Journal of the American Medical Association Network Open 4, no. 10 (2021): e2129639.</Citation></Reference><Reference><Citation>E. J. Brenner, K. N. Weaver, X. Zhang, et al., “Long‐Term Effectiveness and Durability of COVID‐19 Vaccination Among Patients With Inflammatory Bowel Disease,” Clinical Gastroenterology and Hepatology 22, no. 7 (2024): 1475–1486.e4.</Citation></Reference><Reference><Citation>S. Ip, T. L. North, F. Torabi, et al., “Cohort Study of Cardiovascular Safety of Different COVID‐19 Vaccination Doses Among 46 Million Adults in England,” Nature Communications 15, no. 1 (2024): 6085.</Citation></Reference><Reference><Citation>Vaccination Prevents Cognitive Impairment After Breakthrough Infection With SARS‐CoV‐2,” Nature Immunology 25, no. 7 (2024): 1136–1137.</Citation></Reference><Reference><Citation>P. Chan, A. Jorga, F. Caldera, N. Powell, and H. Yun, “P1157 Burden of Herpes Zoster in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Agents,” Journal of Crohn's &amp; Colitis 18, no. Supplement_1 (2024): i2067.</Citation></Reference><Reference><Citation>A. Desai, A. Soni, M. S. Hayney, et al., “Increased Risk of Herpes Zoster in Adult Patients With Inflammatory Bowel Disease After SARS‐CoV‐2 Infection: A Propensity‐Matched Cohort Study,” Inflammatory Bowel Diseases 30, no. 7 (2024): 1094–1102.</Citation></Reference><Reference><Citation>N. Barda, N. Dagan, Y. Ben‐Shlomo, et al., “Safety of the BNT162b2 mRNA Covid‐19 Vaccine in a Nationwide Setting,” New England Journal of Medicine 385, no. 12 (2021): 1078–1090.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>